MRK · 8-K · 20260804PR090045

Revenue Performance and Mix

Merck & Co., Inc. · 2026-08-04 · Importance 49 · Surprise 32 · No source text

Second-quarter 2026 worldwide sales increased 5% year over year to $16.607 billion, or 4% excluding foreign exchange. Pharmaceutical sales rose 5% to $14.760 billion, driven primarily by oncology, cardiometabolic and respiratory products, while Animal Health sales increased 8% to $1.775 billion. KEYTRUDA and KEYTRUDA QLEX sales grew 5% to $8.366 billion, including $463 million from KEYTRUDA QLEX, and WINREVAIR sales increased 75% to $588 million. Animal Health growth included Livestock sales of $1.041 billion, up 8%, and Companion Animal sales of $734 million, up 7%, while JANUVIA/JANUMET fell 31% to $429 million because of U.S. competition and generic competition in China and other international markets.

Key facts

• Total Worldwide Sales were $16.6 Billion in Q2 2026, 5% Growth; 4% Growth ex-FX source
• Total pharmaceutical sales were $14,760 million in Q2 2026, up 5% (4% ex-FX) source
• KEYTRUDA/KEYTRUDA QLEX sales were $8.4 Billion in Q2 2026, 5% Growth; 4% Growth ex-FX; includes KEYTRUDA QLEX Sales of $463 Million source
• Animal Health sales were $1.8 Billion in Q2 2026, 8% Growth; 5% Growth ex-FX source
• WINREVAIR sales were $588 Million in Q2 2026, 75% Growth; 75% Growth ex-FX source
• WELIREG sales were $271 million in Q2 2026, a 67% increase source
• LAGEVRIO sales were $5 million in Q2 2026, a 95% decline source
• JANUVIA/JANUMET sales were $429 million in Q2 2026, a 31% decline source

Impact estimates